Novartis jumps ~6% after remibrutinib clears two Phase 3 MS trials
Novartis (NVS) surged about 6% to $161.10 after remibrutinib cleared two Phase 3 trials in multiple sclerosis. The oral drug delivered fewer relapses and brain lesions versus teriflunomide, without raising liver-safety concerns.
Novartis NYSE:NVS, the Swiss pharmaceutical and oncology giant, rose approximately 6% to $161.10 Tuesday after remibrutinib cleared two major Phase 3 trials in multiple sclerosis. The oral drug showed fewer relapses and brain lesions than teriflunomide, while not increasing the liver-safety concern.